润都股份：获得单硝酸异山梨酯片药品注册证书

Core Viewpoint - Rundu Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for Isosorbide Mononitrate Tablets, which are indicated for the long-term treatment of coronary heart disease, prevention of angina pectoris, treatment of persistent angina after myocardial infarction, and treatment of chronic congestive heart failure in combination with digoxin and/or diuretics [1] Company Summary - Rundu Co., Ltd. has announced the receipt of a drug registration certificate for Isosorbide Mononitrate Tablets [1] - The drug is specifically indicated for multiple cardiovascular conditions, including coronary heart disease and chronic congestive heart failure [1] Industry Summary - The approval of Isosorbide Mononitrate Tablets highlights the ongoing development and regulatory progress within the cardiovascular drug market [1] - The drug's indications suggest a focus on addressing significant health issues related to heart diseases, which are prevalent in the healthcare sector [1]